Local IL‐25 contributes to Th2‐biased inflammatory profiles in nasal polyps

Hong, Haiyu; Chen, F.‐H.; Sun, Yueqi; Hu, Xianting; Wei, Yi; Fan, Yunping; Zhang, J.; Wang, D.‐H.; Xu, Rui; Li, H.‐B.; Shi, Jianbo

doi:10.1111/all.13267

Cited by 53 publications

(74 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients grouped into the high IL-25 expression cohort had higher CT sinus severity scores, higher nasal endoscopy scores, and higher downstream type-2 cytokine levels. 53 In another study, patients with high IL-25 levels were found to have nasal polyps which were more responsive to glucocorticoid therapy, 54 and this finding was corroborated in an in vitro nasal polyp explant model in which steroid exposure reduced IL-25 production. 23 …”

Section: Role Of Epithelial-derived Cytokines In Pathogenesis Of Airwmentioning

confidence: 85%

“…57 In CRSwNP patients, higher levels of IL-33 also correlated with higher CT sinus severity scores, higher nasal endoscopy scores, and higher downstream T H 2 cytokine levels. 53 One group demonstrated that a receptor of IL-33, ST2, is elevated in ethmoid mucosa in CRSwNP patients. 58 Interestingly, ILC2 cells from diseased mucosa from the same patients with CRSwNP produce more IL-13 in response to stimulation with recombinant IL-2 and IL-33, compared to ILC2s from controls.…”

Section: Role Of Epithelial-derived Cytokines In Pathogenesis Of Airwmentioning

confidence: 99%

See 1 more Smart Citation

Sentinels at the wall: epithelial‐derived cytokines serve as triggers of upper airway type 2 inflammation

Patel

Kohanski

Maina

et al. 2018

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

Recent evidence has demonstrated an expanding role of respiratory epithelial cells in immune surveillance and modulation. Studies have been focusing on the earliest events that link epithelial injury to downstream inflammatory responses. Cytokines produced by and released from respiratory epithelial cells are among these early trigger signals. Epithelial-derived cytokines, namely thymic stromal lymphopoietin (TSLP), interleukin (IL)-25, and IL-33, have come to the forefront of recent investigations. Each of these 3 cytokines has been implicated in chronic rhinosinusitis (CRS), asthma, and atopy. Herein we review studies elucidating the roles of epithelial-derived cytokines in the pathobiology of upper airway disease, with particular emphasis on type 2 inflammatory conditions.

show abstract

Section: Role Of Epithelial-derived Cytokines In Pathogenesis Of Airwmentioning

confidence: 85%

Section: Role Of Epithelial-derived Cytokines In Pathogenesis Of Airwmentioning

confidence: 99%

Sentinels at the wall: epithelial‐derived cytokines serve as triggers of upper airway type 2 inflammation

Patel

Kohanski

Maina

et al. 2018

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

show abstract

“…There might be a potential for other soluble factors as markers of Th2 responses. Of specific interest is epithelium‐derived IL‐25, which in contrast to IL‐33 and TSLP was found significantly increased in nasal polyps of chronic rhinitis patients …”

Section: Candidate Biomarkers For Immune Monitoring In Allergen Immunmentioning

confidence: 99%

“…Importantly, a skewed type 2 immune response is initiated with the involvement of cytokines IL‐25, IL‐33, TSLP and type 2 innate lymphoid cells (ILC2). These skew helper‐T‐cell maturation towards the Th2 fate, and direct B cells to induce Ig class switching to IgE, processes mediated by type 2 cytokines IL‐4, IL‐5 and IL‐13 (Figure ). This type 2 skewing persists in an individual, even after the initial response has passed and involuted.…”

Section: Introductionmentioning

confidence: 99%

Recent developments and highlights in immune monitoring of allergen immunotherapy

Zelm

McKenzie

Varese

et al. 2019

Allergy

View full text Add to dashboard Cite

Allergic diseases are the most common chronic immune-mediated disorders and can manifest with an enormous diversity in clinical severity and symptoms. Underlying mechanisms for the adverse immune response to allergens and its downregulation by treatment are still being revealed. As a result, there have been, and still are, major challenges in diagnosis, prediction of disease progression/evolution and treatment.Currently, the only corrective treatment available is allergen immunotherapy (AIT).AIT modifies the immune response through long-term repeated exposure to defined doses of allergen. However, as the treatment usually needs to be continued for several years to be effective, and can be accompanied by adverse reactions, many patients face difficulties completing their schedule. Long-term therapy also potentially incurs high costs. Therefore, there is a great need for objective markers to predict or to monitor individual patient's beneficial changes in immune response during therapy so that efficacy can be identified as early as possible. In this review, we specifically address recent technical developments that have generated new insights into allergic disease pathogenesis, and how these could potentially be translated into routine laboratory assays for disease monitoring during AIT that are relatively inexpensive, robust and scalable. K E Y W O R D Sallergen immunotherapy, allergy, biomarker, immune monitoring | 2343 ZELM Et aL.

show abstract

“…Pro‐inflammatory cytokines modulate LRRK2 mRNA expression suggesting a negative role of LRRK2 during inflammation. Local IL‐25 promotes the production of Th2 cytokines in polyp tissues of CRSwNP and may become of interest as a potential therapeutic target . Myeloid dendritic cells (mDCs) present in nasal polyps have elevated surface expression of IL‐17RB and ST2, suggesting that mDCs might be actively involved in IL‐25‐ and IL‐33‐induced Th2‐type immune responses and eosinophilic inflammation .…”

Section: Novel Highlights On Mechanisms Of Allergic Diseasementioning

confidence: 99%

Highlights and recent developments in airway diseases in EAACI journals (2018)

Bousquet

Akdiş

Grattan

et al. 2019

Allergy

View full text Add to dashboard Cite

The European Academy of Allergy and Clinical Immunology (EAACI) supports three journals: Allergy, Pediatric Allergy and Immunology, and Clinical and Translational Allergy. EAACI's major goals include supporting the promotion of health, in which the prevention of allergy and asthma plays a critical role, and disseminating the knowledge of allergic disease to all stakeholders. In 2018, the remarkable progress in the identification of basic mechanisms of allergic and respiratory diseases as well as the translation of these findings into clinical practice were observed. Last year's highlights include publication of EAACI guidelines for allergen immunotherapy, many EAACI Position Papers covering important aspects for the specialty, better understanding of molecular and cellular mechanisms, identification of biomarkers for disease prediction and progress monitoring, novel prevention and intervention studies, elucidation of mechanisms of multimorbidities, introduction of new drugs to the clinics, recently completed phase three clinical studies, and publication of a large number of allergen immunotherapy studies and meta‐analyses.

show abstract

Local IL‐25 contributes to Th2‐biased inflammatory profiles in nasal polyps

Abstract: Local IL-25 plays a crucial role in promoting Th2-biased inflammatory profiles in NP and may serve as a promising therapeutic target in CRSwNP patients.

Cited by 53 publications

References 36 publications

Sentinels at the wall: epithelial‐derived cytokines serve as triggers of upper airway type 2 inflammation

Sentinels at the wall: epithelial‐derived cytokines serve as triggers of upper airway type 2 inflammation

Recent developments and highlights in immune monitoring of allergen immunotherapy

Highlights and recent developments in airway diseases in EAACI journals (2018)

Contact Info

Product

Resources

About